Purpose Of Review: This review encompasses the recently published information on clonal hematopoiesis of indeterminate potential (CHIP) and discusses its future prospects. By announcing advances in the research of CHIP risk factors and related diseases, with the purpose of offering new insights to treat both hematologic and nonhematologic disorders.
Recent Findings: The majority of studies have shown that CHIP is a common biological condition associated with aging and the incidence of clonal hematopoiesis increases with age. The pathophysiology of blood diseases is projected to be significantly influenced by CHIP. Nevertheless, increasing studies have expanded the application of CHIP to cover nonhematologic diseases such as cardiovascular, renal, liver, and pulmonary diseases. Furthermore, with the fast advancement of genetic testing technology and preventive medicine, the involvement of CHIP in a variety of disorders shows promise as an essential target for preventing disease onset and progression.
Summary: CHIP is linked to a variety of illnesses and has a significant influence on an individual's health outlook. Thus, identifying and managing CHIP is critical for improving the clinical results of the individuals concerned.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOH.0000000000000870 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TET2 deficiency increases the competitive advantage of hematopoietic stem and progenitor cells through upregulation of thrombopoietin receptor signaling.
Nat Commun
March 2025
Department of Medical Biophysics, Temerty Faculty of Medicine, University of Toronto, Toronto, M5G 1L7, Canada.
Ten-Eleven Translocation-2 (TET2) mutations drive the expansion of mutant hematopoietic stem cells (HSCs) in clonal hematopoiesis (CH). However, the precise mechanisms by which TET2 mutations confer a competitive advantage to HSCs remain unclear. Here, through an epigenetic drug screen, we discover that inhibition of disruptor of telomeric silencing 1-like (DOT1L), a H3K79 methyltransferase, selectively reduces the fitness of Tet2 knockout (Tet2) hematopoietic stem and progenitor cells (HSPCs).
View Article and Find Full Text PDFClonal hematopoiesis of indeterminate potential: recent developments and perspectives.
Curr Opin Hematol
March 2025
Key Lab of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine.
Purpose Of Review: This review encompasses the recently published information on clonal hematopoiesis of indeterminate potential (CHIP) and discusses its future prospects. By announcing advances in the research of CHIP risk factors and related diseases, with the purpose of offering new insights to treat both hematologic and nonhematologic disorders.
Recent Findings: The majority of studies have shown that CHIP is a common biological condition associated with aging and the incidence of clonal hematopoiesis increases with age.
Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases.
J Intern Med
March 2025
Department of Big Data in Health Science, Zhejiang University School of Public Health and Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Clonal hematopoiesis of indeterminate potential (CHIP), characterized by the age-related expansion of blood cells carrying preleukemic mutations, is associated with immune aging. This study aimed to investigate the association between CHIP and established autoimmune diseases.
Methods: We analyzed baseline data from 456,692 UK Biobank participants with available whole-exome sequences.
[The state of the art: diagnosis and therapeutic interventions of clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance].
Zhonghua Xue Ye Xue Za Zhi
January 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China Tianjin Institutes of Health Science, Tianjin 301600, China.
Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenias of undetermined significance (CCUS) are included in both fifth edition of the World Health Organization classification (WHO 2022) and International Consensus Classification (ICC). Recently three models were developed for prediction of myeloid neoplasms risk and clinical trials are initiated to investigate potential treatments for CHIP and CCUS. Challenges in diagnosis and therapeutic intervention of CHIP and CCUS were discussed.
View Article and Find Full Text PDFPrevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease.
Bone Marrow Transplant
March 2025
Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!